Skip to main content

Neuroectodermal Tumors clinical trials at UC Health
1 in progress, 0 open to eligible people

  • Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

    Sorry, in progress, not accepting new patients

    Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by the administration of intravenous pembrolizumab (an immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease progression. Funding Source-FDA OOPD

    at UCLA

Last updated: